Cipla Q2 net falls 28.4% to Rs 358 cr, margin slips 850 bps

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Pharmaceutical firm Cipla's second quarter (July-September) consolidated net profit fell 28.4 percent year-on-year to Rs 358 crore while total income from operations increased 14.6 percent to Rs 2,512 crore.

Current year figures include the relevant results of Cipla Medpro and its subsidiaries from the date Cipla Medpro became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable, the company said in its release.

During the same period, consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) fell 16.7 percent Y-o-Y to Rs 564 crore and operating profit margin declined 850 basis points to 22.5 percent.

Domestic revenues, which announced after market hours, grew 11.6 percent year-on-year to Rs 1,040 crore, driven by growth in anti-asthma, urology and COPD therapy segments.

In case of international business, exports of formulations rose 14.9 percent to Rs 1,219 crore and active pharmaceutical ingredients (APIs) increased 17.7 percent to Rs 204 crore, primarily due to growth in anti-retroviral, anti-malaria and anti-allergic segments.

"A year ago period's results included one-time profit share revenues from Escitalopram through US partner," the company said.

The stock closed at Rs 412.55, down 2 percent on the BSE.